Monoclonal Antibody Development Targeting Inflammatory Cytokines for Autoimmune Diseases

The monoclonal antibody development targeting inflammatory cytokines has aroused great attention in different clinical settings. To meet the challenging requirements, Creative Biolabs has built a team of experienced scientists with facilities and processes designed specifically to provide the best strategy and protocols customized to monoclonal antibody discovery services. Till now, we have accomplished a series of projects for identifying the efficacy and safety of several potential antibodies in a range of autoimmune disease models.

Introduction to Inflammatory Cytokines in Autoimmune Diseases

Inflammatory cytokines are a group of protein regulators that play a pivotal role in regulating immune responses. In general, cytokines are essential to a full range of autoimmune-related biological processes, including immune responses, inflammation, cell proliferation, and cell differentiation. Meanwhile, many studies have demonstrated that dysregulation of inflammatory cytokines production can lead to the development of various autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and type I diabetes (T1D). As a consequence, many attempts have been made to confirm the functions of inflammatory cytokines, like tumor necrosis factor-alpha (TNFα), interleukin (IL)-6, IL-17, IL-2, and IL-12, in different autoimmune disease models. For instance, TNFα has been regarded as a pro-inflammatory biomarker in animal models of RA and T1D. Besides, monoclonal antibodies targeting specific inflammatory cytokines or their receptors have been widely generated and used in autoimmune disease therapies.

Fig.1 Engineering techniques for therapeutic antibody innovation.¹

Monoclonal Antibody Development Targeting Inflammatory Cytokines for Autoimmune Diseases

In the past few years of studies, abnormal cellular interactions have been considered as the main causes of autoimmune diseases. As key parts of the cellular network, inflammatory cytokines can regulate the recruitment, survival, expansion of certain cells in autoimmunity. As a well-established company in the bio-industry, Creative Biolabs offers high-quality monoclonal antibody development services for the treatment of autoimmune diseases. Guaranteed to perform within the detailed time frame, and the quality of monoclonal antibodies is always maintained to the end. Furthermore, our laboratory has been equipped with many advanced chemical and biological technologies to support customer’s needs in the fast-growing autoimmune disease therapy research.

By using the comprehensive antibody discovery platform provided by Creative Biolabs, monoclonal antibodies against any cytokines of interest can be developed rapidly. Our antibody libraries provide hits with high affinity, cross-species coverage, and improved drug-like properties. In addition, we also provide a panel of antibody optimization and antibody analysis assays to obtain the sequence and phenotype (affinity and stability) data for deriving meaningful insights on antibody discovery.

Service Highlight

• Integrated solutions for Inflammatory cytokine research
• Well-mature monoclonal antibody development platform
• Precise safety pharmacology studies
• Efficient and cost-effective process
• Reliable data reports

Creative Biolabs provides a global service chain for worldwide customers in the field of drug development for autoimmune diseases. We have accomplished many projects in monoclonal antibody discovery targeting specific inflammatory cytokines. We guarantee the finest results for our customers all over the world. If you are interested in our services, please feel free to contact us for closer communication to learn how we can help your project. Separate services or integrated end-to-end solutions are all welcomed.

Reference

1. Markovics, Adrienn, et al. "Restoring the balance between pro-inflammatory and anti-inflammatory cytokines in the treatment of rheumatoid arthritis: new insights from animal models." Biomedicines 10.1 (2021): 44. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use